FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2943048303> ?p ?o ?g. }

• W2943048303 abstract "Background: Following the PALOMA-3 study results, the combination of palbociclib, a cdk4/6 inhibitor, with fulvestrant has become a standard therapy in women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) whose disease progressed under hormone therapy. Palbociclib increased the progression-free survival (PFS) in all patient subgroups, and no predictive biomarker of palbociclib efficacy has been validated so far. In that context, we evaluated whether early changes of circulating tumor DNA (ctDNA) levels are associated with the efficacy of palbociclib plus fulvestrant. Methods: After providing written informed consent, ER+ HER2- MBC patients were included in a prospective observational cohort (“ALCINA”, NCT02866149) prior to the initiation of palbociclib plus fulvestrant. Tumor response was assessed by a radiological evaluation (RECIST v1.1) every 3 months. Fresh plasma samples were collected at baseline, before the initiation of treatment, at day 15, at day 30 and at disease progression. For each patient, DNA from archived tumor tissue was subjected to targeted NGS to identify a driver mutation. In patients with identified driver mutation, circulating cell-free tumor DNA extracted from plasma was subjected to digital droplet PCR (ddPCR). Ratios of ctDNA levels (J15/baseline and J30/baseline) were correlated with prospectively registered patient characteristics and outcomes. For the current analysis, “responders” were defined as patients who experienced a PFS longer than 3 months. Results: 61 MBC patients have been included and 26 were eligible for ctDNA mutation detection, after the characterization of single nucleotide variations in PIK3CA (N=21 patients), TP53 (N=3) and AKT (N=2). At baseline, 21 patients (81%) had detectable ctDNA levels, with a median level of ctDNA of 381 copies/ml of plasma; There was no significant correlation between ctDNA levels at baseline and PFS (p=0,06). ctDNA levels decreased under therapy, with 82% and 68% of patients displaying detectable levels of ctDNA at day 15 and day 30. Patients with undetectable ctDNA levels at day 15 and, principally, at 30 were more likely to experience a PFS > 3 month (HR=5,8, 95% IC=1,5-22,5, p=0.004). We explored ctDNA level ratios (day 15/baseline and day 30/baseline) and found that all patients whom ctDNA increases at day 30 (31%) will not respond to treatment. Moreover, among all patients, ctDNA detection at day 30 is correlated with shorter PFS [HR=2,634 IC95 (1,1 to 6,5)]. At time of tumor progression, all patients presented increased ctDNA levels. In addition to tumor tissue sequencing, activating ESR1 mutations were found at baseline in 5 patients (19%). Conclusion: Our study suggests that the efficacy of palbociclib and fulvestrant may be monitored by serial analyses of ctDNA levels, before radiological evaluation and that early ctDNA levels and dynamics are prognostics factors for PFS. A large randomized trial, PADA-1 (NCT03079011), is currently testing the utility of real time resistant subclones detection in ctDNA from ER+ HER2- MBC treated with palbociclib and aromatase inhibitor. Citation Format: Darrigues L, Pierga J-Y, Bernard A, Bieche I, Silveira A, Michel M, Sablin M-P, Cottu P, Dubot C, Geiss R, Ricci F, Proudhon C, Bidard F-C. Circulating tumor DNA as a predictive biomarker of response to palbociclib-fulvestrant in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P4-01-20." @default.
• W2943048303 created "2019-05-09" @default.
• W2943048303 creator A5002730822 @default.
• W2943048303 creator A5010391296 @default.
• W2943048303 creator A5034058277 @default.
• W2943048303 creator A5037186009 @default.
• W2943048303 creator A5037964830 @default.
• W2943048303 creator A5043523206 @default.
• W2943048303 creator A5052876034 @default.
• W2943048303 creator A5056852049 @default.
• W2943048303 creator A5070495844 @default.
• W2943048303 creator A5071131635 @default.
• W2943048303 creator A5089331107 @default.
• W2943048303 creator A5090605252 @default.
• W2943048303 creator A5021208621 @default.
• W2943048303 date "2019-02-15" @default.
• W2943048303 modified "2023-10-14" @default.
• W2943048303 title "Abstract P4-01-20: Circulating tumor DNA as a predictive biomarker of response to palbociclib-fulvestrant in patients with estrogen receptor-positive, HER2-negative metastatic breast cancer" @default.
• W2943048303 doi "https://doi.org/10.1158/1538-7445.sabcs18-p4-01-20" @default.
• W2943048303 hasPublicationYear "2019" @default.
• W2943048303 type Work @default.
• W2943048303 sameAs 2943048303 @default.
• W2943048303 citedByCount "0" @default.
• W2943048303 crossrefType "proceedings-article" @default.
• W2943048303 hasAuthorship W2943048303A5002730822 @default.
• W2943048303 hasAuthorship W2943048303A5010391296 @default.
• W2943048303 hasAuthorship W2943048303A5021208621 @default.
• W2943048303 hasAuthorship W2943048303A5034058277 @default.
• W2943048303 hasAuthorship W2943048303A5037186009 @default.
• W2943048303 hasAuthorship W2943048303A5037964830 @default.
• W2943048303 hasAuthorship W2943048303A5043523206 @default.
• W2943048303 hasAuthorship W2943048303A5052876034 @default.
• W2943048303 hasAuthorship W2943048303A5056852049 @default.
• W2943048303 hasAuthorship W2943048303A5070495844 @default.
• W2943048303 hasAuthorship W2943048303A5071131635 @default.
• W2943048303 hasAuthorship W2943048303A5089331107 @default.
• W2943048303 hasAuthorship W2943048303A5090605252 @default.
• W2943048303 hasConcept C121608353 @default.
• W2943048303 hasConcept C126322002 @default.
• W2943048303 hasConcept C143998085 @default.
• W2943048303 hasConcept C151730666 @default.
• W2943048303 hasConcept C2775930923 @default.
• W2943048303 hasConcept C2779343474 @default.
• W2943048303 hasConcept C2779744173 @default.
• W2943048303 hasConcept C2780482068 @default.
• W2943048303 hasConcept C2781197716 @default.
• W2943048303 hasConcept C530470458 @default.
• W2943048303 hasConcept C55493867 @default.
• W2943048303 hasConcept C71924100 @default.
• W2943048303 hasConcept C84606932 @default.
• W2943048303 hasConcept C86803240 @default.
• W2943048303 hasConceptScore W2943048303C121608353 @default.
• W2943048303 hasConceptScore W2943048303C126322002 @default.
• W2943048303 hasConceptScore W2943048303C143998085 @default.
• W2943048303 hasConceptScore W2943048303C151730666 @default.
• W2943048303 hasConceptScore W2943048303C2775930923 @default.
• W2943048303 hasConceptScore W2943048303C2779343474 @default.
• W2943048303 hasConceptScore W2943048303C2779744173 @default.
• W2943048303 hasConceptScore W2943048303C2780482068 @default.
• W2943048303 hasConceptScore W2943048303C2781197716 @default.
• W2943048303 hasConceptScore W2943048303C530470458 @default.
• W2943048303 hasConceptScore W2943048303C55493867 @default.
• W2943048303 hasConceptScore W2943048303C71924100 @default.
• W2943048303 hasConceptScore W2943048303C84606932 @default.
• W2943048303 hasConceptScore W2943048303C86803240 @default.
• W2943048303 hasLocation W29430483031 @default.
• W2943048303 hasOpenAccess W2943048303 @default.
• W2943048303 hasPrimaryLocation W29430483031 @default.
• W2943048303 hasRelatedWork W11161530 @default.
• W2943048303 hasRelatedWork W12242190 @default.
• W2943048303 hasRelatedWork W12293262 @default.
• W2943048303 hasRelatedWork W14228319 @default.
• W2943048303 hasRelatedWork W16909223 @default.
• W2943048303 hasRelatedWork W17295600 @default.
• W2943048303 hasRelatedWork W18725558 @default.
• W2943048303 hasRelatedWork W2083469 @default.
• W2943048303 hasRelatedWork W2422317 @default.
• W2943048303 hasRelatedWork W5387012 @default.
• W2943048303 isParatext "false" @default.
• W2943048303 isRetracted "false" @default.
• W2943048303 magId "2943048303" @default.
• W2943048303 workType "article" @default.